Last reviewed · How we verify
HFA FP MDI
HFA FP MDI is a hydrofluoroalkane-propelled metered-dose inhaler delivering fluticasone propionate, a corticosteroid that reduces airway inflammation by binding glucocorticoid receptors.
HFA FP MDI is a hydrofluoroalkane-propelled metered-dose inhaler delivering fluticasone propionate, a corticosteroid that reduces airway inflammation by binding glucocorticoid receptors. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | HFA FP MDI |
|---|---|
| Sponsor | University of Florida |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate is a potent inhaled corticosteroid that suppresses inflammatory responses in the airways by activating glucocorticoid receptors, leading to decreased production of inflammatory mediators and reduced airway edema and mucus production. The HFA (hydrofluoroalkane) formulation provides improved particle size distribution and lung deposition compared to older CFC propellants, enhancing therapeutic efficacy in asthma and COPD management.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Tremor
- Headache
- Dysphonia
- Palpitations
Key clinical trials
- Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418) (PHASE4)
- Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
- Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
- Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma (PHASE3)
- A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications (PHASE2)
- FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects (PHASE1)
- Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma (PHASE4)
- Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HFA FP MDI CI brief — competitive landscape report
- HFA FP MDI updates RSS · CI watch RSS
- University of Florida portfolio CI